發(fā)布時間：2018-08-24 16:19

【摘要】：目的:觀察靶動脈灌注維拉帕米及化療藥物對中晚期非小細胞肺癌(NSCLC)的有效率(CR+PR)和生存期的影響。方法:對NSCLC患者51例,經(jīng)靶動脈灌注維拉帕米和化療藥物,每月介入治療1次為1療程,每例治療2-4個療程后,評估近期療效,對51例中治療后滿3年的38例隨訪1、2、3年生存率。結(jié)果:51例中晚期NSCLC患者,評估近期療效,完全緩解(CR)5例(9.80%),部分緩解(PR)36例(70.59%),總有效率(CR+PR)為80.39%。38例NSCLC患者評估遠期療效,中位生存時間為24.0月,l、2、3年生存率分別為76.3%(29/38)、55.3%(21/38)和26.3%(10/38);其中22例鱗癌中位無進展期時間為17.0月,13例腺癌中位無進展期時間為10.0月。在對51例患者的毒副反應評價中發(fā)現(xiàn),15例患者(31.37%)出現(xiàn)白細胞下降,12例(23.53%)出現(xiàn)I-II級的消化道反應的不良反應。51例患者未見維拉帕米相關(guān)的心血管副作用。結(jié)論:靶動脈灌注維拉帕米聯(lián)合化療藥物對于中晚期NSCLC患者的近期、遠期療效確切,部分患者可獲得手術(shù)及根治性放療的機會。無明顯副作用,患者可耐受�？墒共糠只颊吣[瘤降期降級,能在一定程度上延長患者生存時間。
[Abstract]:Aim: to observe the effect of target artery infusion of verapamil and chemotherapeutic drugs on the effective (CR PR) and survival time of (NSCLC) in patients with advanced non-small cell lung cancer (NSCLC). Methods: a total of 51 patients with NSCLC were treated with verapamil and chemotherapeutic drugs via target artery. One course of interventional therapy was used once a month. After 2-4 courses of treatment, the short-term effect was evaluated. 38 cases of 51 patients with NSCLC were followed up for 1, 2 and 3 years after 3 years of treatment. Results in 51 cases of middle and late stage NSCLC, 5 cases (9.80%) had complete remission of (CR) and 36 cases (70.59%) had partial remission of (PR). The total effective rate of (CR PR) was 80.39%. 38 cases of NSCLC were evaluated for long-term curative effect. The median survival time was 24.0 months and the 3-year survival rate was 76.3% (29 / 38), 55.3% (21 / 38) and 26.3% (10 / 38), respectively, and the median non-progression time of 22 cases of squamous cell carcinoma was 17.0 months and 13 cases of adenocarcinoma was 10.0 months. Among 51 patients, 15 (31.37%) had leukocytopenia and 12 (23.53%) had I-II grade digestive tract reaction. There were no cardiovascular side effects associated with verapamil in 51 patients. Conclusion: the short-term and long-term curative effect of target artery infusion of verapamil combined with chemotherapeutic drugs in patients with intermediate and advanced NSCLC is definite, and some patients can obtain the opportunity of operation and radical radiotherapy. No obvious side effects, the patient can tolerate. It can reduce the tumor stage and prolong the survival time to some extent.
【學位授予單位】：皖南醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2

【參考文獻】

相關(guān)期刊論文 前10條

1 劉華麗;胡偉國;宋啟斌;;Ⅲ期非小細胞肺癌非手術(shù)治療的現(xiàn)狀與研究進展[J];腫瘤學雜志;2016年02期

2 魏家瑋;郭述良;;支氣管動脈灌注化療與全身靜脈化療對晚期非小細胞肺癌患者療效及不良反應發(fā)生率的META分析[J];中華肺部疾病雜志(電子版);2015年03期

3 李躍軍;卓德斌;;ABCG2、MDR1基因表達水平與5-氟尿嘧啶耐藥的CD44+SGC-7901/5-Fu多藥耐藥關(guān)系[J];中國老年學雜志;2014年18期

4 梁麗峰;戢福云;馬李杰;趙詣林;陳向軍;金發(fā)光;;肺癌獲得性多藥耐藥機制的研究進展[J];國際呼吸雜志;2014年14期

5 趙真真;王忠敏;茅愛武;;非小細胞肺癌的介入治療現(xiàn)狀[J];介入放射學雜志;2014年03期

6 袁紅;陸舜;;肺鱗癌靶向治療研究現(xiàn)狀[J];中國肺癌雜志;2013年10期

7 朱磊;段巧虹;范平生;李繼德;童少明;俞修坤;魏強;;靶動脈灌注維拉帕米對晚期食管癌介入療效的臨床觀察[J];安徽醫(yī)學;2011年11期

8 劉亞貝;李燁;唐艷;陳曼萍;胡冰;林新民;魯朝暉;范平生;;維拉帕米聯(lián)合化療藥物治療惡性胸腹水的臨床觀察[J];安徽醫(yī)藥;2010年04期

9 劉穎;王麗莉;;米非司酮調(diào)控卵巢癌細胞表達葡萄糖神經(jīng)酰氨合成酶并逆轉(zhuǎn)其多藥耐藥性[J];南方醫(yī)科大學學報;2008年09期

10 肖湘生;董生;董偉華;張電波;李相生;史景云;;肺癌血供系列研究[J];介入放射學雜志;2008年03期

，

本文編號：2201355